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Abstract. 
 
We have begun to explore the mechanisms 
of apoptosis using a cell-free system based on extracts 
from 
 
Xenopus
 
 eggs. Nuclei assembled or placed in 
these extracts undergo the morphological changes typi-
cal of apoptosis and eventually disintegrate. We used 
this system to investigate the potential involvement in 
apoptosis of proteins containing Src homology 2 (SH2) 
domains, which are known to interact with specific ty-
rosine-phosphorylated ligands. SH2 domains from a 
number of signaling proteins, including Lck, Src, and 
Abl, inhibited apoptosis when present at concentra-
tions of 10–100 nM. The inhibition was dependent on 
specific interaction with endogenous tyrosine-phosphor-
ylated ligands. A synthetic peptide ligand for Src family 
SH2 domains also inhibited apoptosis in a phosphotyr-
osine-dependent manner. Kinetic analysis defined 
three phases in the apoptotic process occurring in this 
cell-free system. SH2 domains and ceramide act 
throughout the first 60–90 min of the process (the “ini-
tiation” phase). Next, Bcl-2, interleukin-1
 
b
 
 converting 
enzyme family(CPP32-like) proteases, and the heavy 
 
membrane fraction act in a period occurring 
 
z
 
90–120 
min after the start of incubation (the “sentencing” 
phase). In the final phase (“execution”), the process of 
active nuclear destruction ensues.
 
A
 
poptosis 
 
is a normal physiological process of cell
death observed in multicellular organisms (for re-
views see 7, 34, 37, 42, 45, 46). The apoptotic death
pathway can be initiated by a variety of stimuli, including
DNA damage, the withdrawal of growth factors, and the
binding of certain ligands to cell surface receptors. Al-
though the death stimulus and cellular context can vary
widely, it is thought that apoptosis involves a conserved
biochemical machinery. Supporting this notion of a com-
mon pathway are several observations: first, apoptotic
cells undergo a stereotypical sequence of morphological
changes, including plasma membrane blebbing, chromatin
condensation, and the shrinkage and fragmentation of the
nucleus and cytoplasm, resulting in the formation of cell
fragments termed “apoptotic bodies.” Second, endonu-
cleases and proteases are usually activated, causing the
fragmentation of genomic DNA and the cleavage of cer-
tain proteins such as fodrin (25), nuclear lamins (19, 33),
and poly (ADP-ribose) polymerase (16, 20, 31, 40). Fi-
nally, there are a number of proteins whose function in
regulating apoptosis is conserved phylogenetically. For ex-
ample, the human Bcl-2 protein can inhibit apoptosis
when expressed in the cells of a variety of species, includ-
ing the nematode, 
 
Caenorhabditis elegans
 
 (e.g., 15, 32, 37,
44, 45). Bcl-2 belongs to a family of proteins (for reviews
 
see 32, 37). Some members of this family, e.g., Bcl-2, Bcl-x
 
L
 
,
 
C. elegans
 
 Ced-9, and the adenovirus E1B 19-kD protein,
are able to inhibit apoptosis. Others, such as Bax, Bad,
Bcl-xS, and Bak (1, 9, 17), have the opposite effect of pro-
moting cell death. Thus, cell survival may be regulated in
part by the ratio of Bcl-2–type to Bax-type molecules (38,
47, 49).
Also showing conserved function in apoptosis is a large
family of cysteine proteases related to the 
 
C. elegans
 
 pro-
tein, Ced-3 (50), and the vertebrate protein, interleukin-1
 
b
 
converting enzyme (ICE)
 
1
 
 (26). Most recently, a particular
subfamily of these enzymes, consisting of Ced-3, CPP-32/
Yama/Apopain (5, 11, 30, 39, 43), MCH2 (12), and ICE-
LAP3/CMH-1/MCH3 (6, 13, 21), has been suggested to
play a central part in the apoptotic process.
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1. 
 
Abbreviations used in this paper
 
: GST, glutathione-
 
S
 
-transferase; HM,
heavy membrane; ICE, interleukin-1
 
b
 
 converting enzyme; PLC, phospho-
lipase C; PTyr, phosphotyrosine; SH2, Src homology 2.
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The precise roles of these molecules in the death path-
way, as well as the identities of other molecular partici-
pants in the process, remain to be elucidated. We recently
described a novel cell-free system that may help to unravel
aspects of apoptotic biochemistry and the function of Bcl-2
(29). This system is based on extracts from eggs of the
South African clawed frog, 
 
Xenopus laevis
 
. 
 
Xenopus
 
 egg
extracts have been an important tool for studying cellular
processes such as nuclear membrane assembly, nuclear
protein import, DNA replication, and cell cycle regulation
(for review see 28). We found that it was also possible to
prepare “apoptotic” extracts that mimic the nuclear shrink-
age, chromatin condensation, and DNA fragmentation ob-
served in cells dying by apoptosis (29). Apoptotic activity
in these extracts requires the presence of a heavy mem-
brane (HM) fraction consisting mostly of mitochondria and
is inhibited by the addition of baculovirus-expressed Bcl-2
protein. Moreover, we found that apoptosis in this system
involves a latent phase, lasting 
 
z
 
90–120 min, that occurs
whether or not nuclei are present. Protection by Bcl-2 oc-
curs only if Bcl-2 is present during this latent period; thus,
it would appear that the antiapoptotic role of Bel-2 is due
primarily to its interaction with cytoplasmic, rather than
nuclear, targets.
Apoptosis in the 
 
Xenopus
 
 system is not affected by in-
hibitors of tyrosine phosphorylation such as herbimycin A
(29) and genistein (see Results). Thus, protein tyrosine ki-
nases are apparently not involved in the portion of the cell
death pathway at work in the cell-free system. However,
free phosphotyrosine (PTyr; 10–20 mM) was found to
have a marked inhibitory activity (29). This suggested that
protein tyrosine phosphatases or other molecules interact-
ing with tyrosine-phosphorylated proteins might be impor-
tant for apoptosis in this system. We were thus led to ex-
plore the possibility that Src Homology 2 (SH2) domains
are involved in the apoptotic pathway. SH2 domains (for
reviews see 2, 36) are a type of modular sequence element
often found in signaling molecules. These domains are
known to interact with specific protein sequences contain-
ing phosphorylated tyrosine residues. The binding of SH2
domains to their ligands provides a means for the cell to
assemble protein complexes in a manner readily con-
trolled by tyrosine kinases and phosphatases. We now
show that the SH2 domains from certain signaling pro-
teins, when added to the 
 
Xenopus
 
 cell-free system in the
form of glutathione-
 
S
 
-transferase (GST) fusion proteins,
can inhibit apoptosis. Moreover, apoptosis in this system is
inhibited by a synthetic peptide known to interact with the
SH2 domains of Src family kinases; this effect is dependent
on tyrosine phosphorylation of the ligand peptide.
The data support a role of SH2–PTyr interactions in the
apoptotic pathway. Moreover, our investigations show that
the events controlled by SH2 domain interactions, ceramide,
Bcl-2, CPP32-like proteases, and the HM fraction define
two distinct temporal phases in the apoptotic process. These
phases precede a third stage, during which the nuclei are
actively destroyed.
 
Materials and Methods
 
The preparation, fractionation, and use of 
 
Xenopus
 
 egg extracts were as
described (28, 29). In experiments with unfractionated extracts, 50 
 
m
 
l of
extract was mixed with ATP-regenerating system (consisting of 2.5 
 
m
 
l of a
200 mM solution of phosphocreatine, 1 
 
m
 
l of a 100 mM solution of ATP,
pH 7.0, and 1.5 
 
m
 
l of a solution of creatine phosphokinase (5 mg/ml; Sigma
Chemical Co., St. Louis). Then, 1–3 
 
m
 
l of a suspension of rat liver nuclei
(at 
 
z
 
10
 
6
 
 nuclei per 
 
m
 
l) was added, as well as 1 
 
m
 
l of rhodamine-labeled
nuclear import substrate (TRITC-HSA–NLS [a TRITC-labeled conjugate
of human serum albumin with a synthetic nuclear localization signal pep-
tide]) to monitor nuclear intactness, as described (28). GST–SH2 domain
fusions and synthetic peptides were then added from stock solutions at
20–50 times the final concentration. HM-depleted extracts were reconsti-
tuted from 45 
 
m
 
l of egg cytosol and 5 
 
m
 
l of light membrane suspension ob-
tained from M-phase extracts, as described (28).
The expression and purification of GST fusion proteins were as de-
scribed (4). Briefly stated, the GST–SH2 domains of Lck were produced
by PCR amplification of the desired region of wild-type (Y192), F192, and
E192 Lck constructs (amino acids 121–224), using the proofreading Vent
DNA polymerase (New England Biolabs, Beverly, MA). The PCR frag-
ments were inserted in frame into the pGEX-3T prokaryotic expression
vector (14), and the resulting GST–SH2 fusion proteins were purified by
glutathione–Sepharose affinity chromatography. The fusion proteins were
dialyzed (using a microdialysis apparatus [Pierce Chemical Co., Rockford,
IL]) against a buffer containing Hepes (20 mM) and KCl (50 mM) before
use. Synthetic peptides were obtained from Research Genetics (Hunts-
ville, AL).
Phosphorylation of the synthetic peptide (RNLDNGGFYIAPR) com-
prising the site surrounding Y192 in Lck was assayed essentially as de-
scribed previously (27): peptide (4 mg/ml), 
 
g
 
-[
 
32
 
P]ATP (1 mCi/ml), and
 
Xenopus
 
 egg extract (7.4% vol/vol, corresponding to a protein concentra-
tion of 
 
z
 
2.6 mg/ml) were incubated at 22
 
8
 
C for the times indicated, in 25 
 
m
 
l of
a buffer containing 50 mM Hepes/K, pH 7.4, 10 mM MgCl
 
2
 
, 5 mM MnCl
 
2
 
,
and 1.2 mM Na
 
3
 
VO
 
4
 
. The reaction was stopped with the addition of 155 
 
m
 
l
of 3.2% TCA and 20 
 
m
 
l of a solution of BSA (10 mg/ml). After 30 min on
ice, the samples were centrifuged, and 100 
 
m
 
l of each supernatant was ap-
plied to a 2.5-cm circle of phosphocellulose membrane (Whatman P-81).
The filters were washed seven to eight times in 75 mM 
 
o
 
-phosphoric acid
in 50-ml conical tubes. After drying, the filters were placed in 4 ml of
scintillation fluid and the radioactivity was counted. All the results pre-
sented here were qualitatively reproducible. However, the time at which
Figure 1. SH2 domains from Abl and Src inhibit apoptosis in the
cell-free system. GST fusions of the SH2 domains of c-Abl and
c-Src were added, at the indicated concentrations, to an apoptotic
egg extract containing sperm chromatin. The fraction of intact
nuclei was assayed at various times thereafter, as previously de-
scribed (29). 
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nuclear destruction began to occur varied from extract to extract, making
it impossible to average the results from separate experiments in a mean-
ingful way. Each figure is representative of at least four experiments giv-
ing similar results.
 
Results
 
GST–SH2 Domain Fusions Specifically Inhibit 
Apoptotic Activity in the Cell-free System
 
To investigate whether SH2–PTyr interactions are in-
volved in the cell-free apoptosis system, we prepared GST
fusion proteins containing the SH2 domains from several
signaling proteins and added them to the extracts. Fig. 1
shows that the SH2 domains from c-Src and c-Abl pro-
duced a concentration-dependent inhibition of apoptosis
when present at concentrations of 
 
>
 
10 nM. A similar ef-
fect was seen when fusions of GST with the SH2 domains
of Grb-2 and Stat1 were added (not shown).
To determine whether the effects of SH2 domains
added to the cell-free system were based on specific inter-
actions with phosphorylated ligands, we took advantage of
point mutations in the SH2 domain of Lck that disrupt
PTyr-dependent binding. Previous studies (4) had shown
that the function of the Lck SH2 domain can be regulated
by modification of a particular amino acid residue, Y192.
Phosphorylation at this site, which is located next to the
EF loop of the SH2 domain, markedly lowers the affinity
of the SH2 domain for phosphotyrosine-containing pro-
tein ligands. Mutants in which this Tyr residue was changed
to Phe (F192) and Glu (E192) had been found to mimic
the unphosphorylated and phosphorylated states, respec-
tively, of Y192. We added the wild-type and mutant Lck
SH2s to the 
 
Xenopus
 
 cell-free system. As shown in Fig. 2,
the SH2 domain from the constitutively inactive Lck-E192
mutant was unable to inhibit apoptosis. On the other hand,
the Lck-F192 mutant SH2, which binds constitutively to
phosphotyrosine-containing ligands, was as potent an in-
hibitor as the Src and Abl SH2 domains.
The wild-type Lck SH2 domain, like the nonbinding
E192 mutant, was unable to inhibit apoptosis. This result
could be explained if we supposed that the wild-type Lck
SH2 domain became phosphorylated on Y192 by a kinase
present in the extract and consequently had a lowered af-
finity for the tyrosine phosphorylated ligand, similar to the
E192 mutant. This hypothesis predicted that if phosphory-
lation on Y192 were prevented, the wild-type SH2 domain
would function like Lck-F192; i.e., it would inhibit apopto-
sis in the cell-free system. To test this prediction, we added
the tyrosine kinase inhibitor, genistein, either separately
or with the wild-type Lck SH2 domain. Genistein, added
by itself, had only a slight effect on the kinetics of nuclear
destruction in the apoptotic cell-free system (Figs. 3 and
4 
 
B
 
; this suggests that any critical tyrosine phosphorylation
events involving proteins endogenous to the extract had
already occurred before the addition of genistein). How-
Figure 2. Effect of wild-type and mutant SH2 domains from Lck.
The experiment was performed as in Fig. 1. GST–SH2 domain fu-
sions were added at 100 nM. Note that the wild-type (Y192) Lck
SH2 domain is unable to inhibit apoptosis, as is the E192 mutant,
which mimics the phosphorylated form of Y192. However, the
F192 mutant, which mimics the unphosphorylated form of Y192,
inhibits apoptosis in the extract.
Figure 3. The wild-type Lck SH2 domain is inactive in the extract
because it becomes phosphorylated. (A) Genistein, an inhibitor
of tyrosine kinases, restored the ability of the wild-type Lck SH2
domain to inhibit apoptosis. The experiment was done as in Fig.
2, except that genistein (10 mM) was added to the indicated sam-
ples either separately or along with the wild-type (WT) Lck SH2
domain–GST fusion (100 nM). (B) A kinase in the Xenopus egg
extract can phosphorylate a synthetic peptide corresponding to
the site surrounding Y192 in Lck. The peptide (RNLDNGGFY-
IAPR) was incubated in a buffer containing g-[32P]ATP and Xe-
nopus egg extract (diluted as described in Materials and Methods)
for the times indicated, and the incorporated radioactivity was as-
sayed (see Materials and Methods). Two separate experiments
are shown. 
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ever, the coaddition of genistein and the wild-type Lck SH2
domain produced a marked inhibitory effect, similar to that
of the F192 mutant (Fig. 3 
 
A
 
). Therefore, the Lck SH2 do-
main is likely to be phosphorylated on Y192 by an endoge-
nous protein tyrosine kinase in the 
 
Xenopus
 
 egg extracts,
and thus inactivated. To examine this more directly, we as-
sayed the phosphorylation of a synthetic peptide corre-
sponding to the sequence surrounding Y192. Fig. 3 
 
B
 
shows that this peptide is phosphorylated by the extract in
a time-dependent manner; the specific activity was esti-
mated at 7.7 
 
6
 
 0.2 pmol per min per mg of extract protein.
Thus, a kinase is present in the extract that is able to phos-
phorylate this site in the Lck SH2 domain. We conclude
from the experiments shown in Figs. 1–3 that the effects of
the exogenous SH2 domains are dependent on specific in-
teractions with endogenous tyrosine-phosphorylated ligands.
To confirm that PTyr–SH2 domain interactions are im-
portant for apoptosis in the cell-free system, we examined
the effects of adding an exogenous synthetic phosphopep-
tide, EPQY*EEIPIYLK (abbreviated Y*EEI; Y* repre-
sents PTyr), known to interact with Src family SH2 do-
mains (41). Fig. 4 
 
A
 
 shows that this peptide was able to
inhibit apoptosis even at concentrations as low as 1 nM. In
control experiments (Fig. 4 
 
B
 
), we found that a nonphos-
phorylatable mutant peptide, EPQFEEIPIYLK (FEEI),
was ineffective, arguing again that the inhibitory effect is
dependent on the specific interaction of SH2 domains with
sequences containing PTyr residues. The effect of adding
the unphosphorylated peptide (YEEI) was similar to that
seen with Y*EEI, suggesting that YEEI can be phosphor-
ylated by kinases endogenous to the extract (Fig. 4 
 
B
 
). In
support of this idea, we found that the protein tyrosine
kinase inhibitor, genistein, was able to reverse the inhibi-
tory effect of YEEI (Fig. 4 
 
B
 
). To probe the specificity
of these effects further, we tested another synthetic phos-
phopeptide, corresponding to the SH2 domain–binding re-
gion surrounding residue Y1021 of phospholipase-C
 
g
 
1
(DNDY*IIPLPDPK; 35). This peptide had no significant
effect on the apoptotic process in the cell-free system, even
at concentrations as high as 1 
 
m
 
M (see Fig. A1). This is ad-
ditional evidence that interactions involving specific SH2
domains are important in the 
 
Xenopus
 
 system.
Figure 4. A synthetic peptide ligand for Src family SH2 domains,
EPQY*EEIPIYLK (Y*EEI), inhibits apoptosis in the Xenopus
cell-free system in a PTyr-dependent manner. (A) The indicated
concentrations of phosphopeptide were added at the start of in-
cubation. (B) (Top) The phosphopeptide (denoted by Y*EEI)
was added to the extract at a final concentration of 5 nM, in the
presence or absence of genistein. Genistein has no effect on its
activity. (Bottom) The unphosphorylated form of this peptide
(YEEI) and an unphosphorylatable mutant peptide (FEEI) were
added at 5 nM. Note that the FEEI peptide has no inhibitory ac-
tivity. The unphosphorylated peptide (YEEI) inhibits apoptosis
nearly as well as the Y*EEI, but this inhibition is reversed in the
presence of genistein. Thus, the peptide is apparently phosphory-
lated by a kinase present in the extract.
Figure 5. The Src SH2 domain inhibits an activity important in
the early portion of the apoptotic process. The experiment was
performed as above, except that the GST–Src SH2 fusion was
added (final concentration 100 nM) at the indicated times after
the start of incubation. 
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SH2 Domains Interact in the Early Phase of the 
Apoptotic Process
 
To determine when in the apoptotic process PTyr–SH2 in-
teractions are important, we performed experiments in
which the Src SH2 domain–GST fusion was added to the
cell-free system at various times after the start of incuba-
tion (Fig. 5). As before (Fig. 1), the Src SH2 domain
slowed the kinetics of nuclear destruction markedly when
added at the start of incubation. However, when the addi-
tion of this SH2 domain was delayed by intervals ranging
from 30–120 min, its inhibitory activity was gradually re-
duced. These results demonstrate that the SH2 domain in-
teractions are important throughout the initial portion of
the apoptotic process.
 
Bcl-2 and the Heavy Membrane Fraction Act Later 
Than SH2 Domains in the Apoptotic Process
 
Previously, we showed that Bcl-2 can inhibit apoptosis by
acting during the early cytoplasmic phase of the apoptotic
process (29). To define more precisely the period during
which Bcl-2 acts, we performed experiments similar to
those described above. Bcl-2 was added at various inter-
vals after the start of incubation, and the time course of
nuclear survival was determined. Unlike the SH2 domains,
Bcl-2 inhibited apoptosis effectively even if its addition
was delayed up to 
 
z
 
1.5 h (Fig. 6). Thus, it would appear
that the events controlled by Bcl-2 occur later in the apop-
totic process than those regulated by SH2 domain–PTyr
interactions.
Our previous studies also identified a requirement for
an HM fraction that was enriched in mitochondria but also
contained other membrane material (29). Extracts de-
pleted of heavy membranes were found to lack apoptotic
activity, and the addition of HMs restored this activity in a
dose-dependent manner. To determine when the HM frac-
tion is required during the time course of the apoptotic
process occurring in the cell-free system, we performed an
experiment in which the HM fraction was added at various
times after the start of incubation. Fig. 7 shows that delay-
ing the addition of the HM fraction by as much as 1.5 h
had essentially no effect on the kinetics of nuclear destruc-
tion in the apoptotic extract. Only when the HM fraction
was added at 2 h after the start of incubation was the time
course of nuclear destruction delayed. We conclude that,
like Bcl-2, the heavy membranes are required at a rela-
tively late stage in the apoptotic process.
We also showed previously that a soluble ceramide ana-
log could substitute for the HM fraction in the cell-free
apoptotic system (24) This finding raised the possibility
that the function of HMs was simply to produce ceramide.
However, as Fig. 8 shows, ceramide acts earlier in the ap-
optotic process than the HMs. Like the GST–SH2 domain
fusions, ceramide was most active when added at the start
of incubation, and its potency declined gradually as the
time of its addition was delayed. Thus, it is unlikely that
the function of HMs is merely to produce ceramide.
Previous studies from many laboratories have demon-
strated the involvement of cysteine proteases from the
Ced-3/ICE family in the apoptotic process (see Introduc-
Figure 6. The Bcl-2 protein acts later in the apoptotic process, af-
ter z1.5 h of incubation. Lysates from Sf9 cells (0.01 vol, as de-
scribed; 29) infected with Bcl-2 baculovirus or, as a control, b-galac-
tosidase baculovirus were added at the indicated times after the
start of incubation. Note that Bcl-2 is much less effective when its
addition is delayed at least z2 h after the start of incubation.
Figure 7. The heavy membrane (HM) fraction is required rela-
tively late in the apoptotic process. Percoll-enriched HMs (29)
were added at the indicated times. Note that only when the HMs
were added at least 2 h after the start of incubation was there any
significant delay in the kinetics of nuclear destruction.
Figure 8. Ceramide acts early in the cell-free apoptotic process.
A progressive loss of activity occurs when the addition of ceramide
(150 mM) is delayed 0.5–1 h. 
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tion). To determine whether such proteases are involved
in the 
 
Xenopus
 
 system, we tested the effects of aldehyde-
based tetrapeptide derivatives that have been shown to be
specific inhibitors of ICE family proteases. The compound
Ac-DEVD-CHO (DEVD) has been shown to inhibit
CPP32-like proteases preferentially, while Ac-YVAD-CHO
(YVAD) is more selective for ICE and its close relatives
(30). Fig. 9 
 
A
 
 shows that micromolar concentrations of
DEVD block apoptosis in the 
 
Xenopus
 
 system. YVAD also
inhibited apoptosis in this system, but concentrations
 
z
 
500-fold higher were required. These results are similar
to those described by Nicholson et al. (1995) (30) for mam-
malian cells, and argue that a CPP32-like, rather than an
ICE-like, protease activity is required for apoptosis in the
 
Xenopus
 
 cell-free system. However, because these com-
pounds can inhibit multiple caspases, it is possible that sev-
eral such enzymes are involved in this system. After this
manuscript was submitted, other studies showed directly
that CPP32-like caspases are activated in 
 
Xenopus
 
 egg ex-
tracts (3, 18).
Using the same approach as described above, we investi-
gated the effect of delaying the addition of DEVD. The re-
sults (Fig. 9 
 
B
 
) showed that the protease activity was re-
quired relatively late in the apoptotic process, near the end
of the 1.5–2-h latent phase. In this experiment, when Ac-
DEVD-CHO was added as late as 1 h after the start of the
incubation, almost no reduction in its inhibitory activity
was seen, and only a partial loss of activity was observed
when the inhibitor was added after 1.5 h of incubation. In
contrast, the inhibitor had no activity when added after 2 h.
 
Discussion
 
A Role for SH2 Domains in Apoptosis
 
In this report, we have shown that apoptosis in the 
 
Xeno-
pus
 
 cell-free system is inhibited by the addition of SH2 do-
mains from several signaling proteins (Figs. 1–3 and 5).
Our results with the Lck SH2 domain (Figs. 2 and 3) dem-
onstrate that the effect is specifically due to interaction
with tyrosine-phosphorylated ligands, in that it is abro-
gated by phosphorylation on residue Y192 of Lck; phosphor-
ylation at this site was shown elsewhere to disrupt binding
of the SH2 domain to tyrosine-phosphorylated ligands (4).
Similarly, the inhibition produced by the ligand peptide,
YEEI, was dependent on phosphorylation of the tyrosine
residue required for interaction with SH2 domains. Thus,
our results show specificity in the sense that they reflect the
PTyr-dependent binding of SH2 domains and their ligands.
On the other hand, the exogenous SH2 domains appear to
be acting in a generic manner, inasmuch as the SH2 do-
mains from a number of proteins can block apoptosis in
this system when present at concentrations of at least 10 nM.
Our results therefore do not identify which particular
SH2-containing protein(s) and corresponding tyrosine-
phosphorylated ligand(s) are involved in the cell-free apop-
tosis system.
The synthetic phosphopeptide Y*EEI inhibited apopto-
sis in the extract at lower concentrations than those re-
quired for the GST–SH2 domain fusions. The reason for
this is unclear. Possibly these reagents act in different
Figure 9. CPP32-like protease
activity is required for apop-
tosis in the Xenopus system.
The crucial proteolytic event
occurs  z1.5–2 h after the
start of incubation. (A) The
tetrapeptide inhibitors, Ac-
DEVD-CHO (DEVD) and
Ac-YVAD-CHO (YVAD),
were added to the extract
from the start of incubation
at the concentrations indi-
cated. Nuclear survival was
quantitated at various times.
(B) The experiment was per-
formed as above, except that
DEVD (100 mM) was added
at the indicated times. Note
that the inhibitor lost its ef-
fect only when added after
z2 h of incubation. (C and
D) Fluorescence photomi-
crographs of rat liver nuclei
placed in apoptotic extract,
incubated for 3 h in the pres-
ence (C) or absence (D) of
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ways, e.g., by interacting in a regulatory manner with spe-
cific molecules. However, we consider it likely that these
molecules act by disrupting PTyr-dependent interactions
between proteins endogenous to the extract. What could
be the function of these endogenous proteins? SH2 do-
mains are frequently found in signaling molecules that reg-
ulate cell proliferation. Such molecules include tyrosine ki-
nases, tyrosine phosphatases, and the adapter molecules
(e.g., Grb2) that link these enzymes to other members of
signaling cascades. Grb3-3, a naturally occurring variant of
Grb2 that contains a truncated, nonfunctional SH2 do-
main, was found to promote apoptosis, presumably by act-
ing as a dominant negative inhibitor of a cell survival path-
way (10). Our results (Figs. 1–5) are just the opposite: i.e.,
they suggest that some SH2 domains can be involved in
promoting cell death, not survival. We suggest that the fate
of the cell may rest in the balance between apoptotic and
survival pathways, both controlled in part by SH2 domain
interactions. After this manuscript was submitted, it was
reported that c-Crk, an adapter protein containing an SH2
domain, is required for apoptosis in Xenopus egg extracts,
and that the SH2 domain of Crk inhibits apoptosis po-
tently in this system (8). The activity of Crk could account
for our results; however, an involvement of other proteins
containing SH2 domains cannot be excluded at present.
In view of our findings that suggest a role for PTyr–SH2
domain interactions in apoptosis, it may seem surprising
that genistein, an inhibitor of multiple tyrosine kinases,
has little or no effect on apoptosis in the Xenopus system.
This paradox can be resolved if we suppose either that the
critical phosphorylation events have already taken place
before the preparation of the extracts, or that the kinases
responsible for these critical phosphorylation events are
insensitive to genistein. We have also observed that per-
vanadate (1–10 mM), an inhibitor of protein tyrosine phos-
phatases, inhibits apoptosis effectively in the Xenopus sys-
tem (unpublished data; this inhibition is not merely due to
the presence of peroxide in the pervanadate preparation,
as control experiments with added H2O2 [10 mM] showed
no effect on the kinetics of apoptosis). This result may sug-
gest that tyrosine dephosphorylation of specific proteins is
required for the apoptotic process in the Xenopus system.
However, it is also possible that pervanadate blocks apop-
tosis by inhibiting activities other than phosphatases.
The Relationship of Ceramide and the Heavy 
Membrane Fraction
The role of the heavy membrane fraction is still under in-
vestigation. Previously we reported that a soluble ceramide
analog can induce apoptosis in HM-depleted extracts (24).
Further experiments have shown that this effect is appar-
ently due to the synergistic effect of ceramide and a small
amount of contaminating heavy membranes still remaining
in the HM-depleted extracts (Farschon, D.M., and D.D.
Newmeyer, unpublished results). We note that both the
production of ceramide and the molecules that respond to
ceramide are reported to reside in the plasma membrane
(e.g., 22). If so, to explain the activity of ceramide in HM-
depleted extracts, we would need to postulate that some
amount of contaminating plasma membrane–derived ma-
terial is present. The HM fraction could also contain a cer-
tain amount of such membranes. Thus, we considered the
possibility that the function of our HM preparation was
simply to increase the amount of plasma membrane–pro-
ducing ceramide. However, as Figs. 7 and 8 show, time-
dependent changes occur in the cell-free system that at
first diminish its responsiveness to ceramide and later
make it responsive to the HM fraction. Thus, it is unlikely
that the function of HMs is merely to produce ceramide.
Recent studies have shown that, during apoptosis, mito-
chondria release cytochrome c into the cytosol, leading to
the activation of CPP32-like proteases. Bcl-2, through its
interactions with the outer mitochondrial membrane,
blocks the efflux of cytochrome c (18a, 18, 48). Whether
ceramide can directly or indirectly modulate the release of
cytochrome c from mitochondria is still unknown.
Temporal Stages in Apoptosis
Apoptosis could be envisioned as occurring in three
stages. The first of these, “initiation,” would refer to the
events that cause entry into the common death pathway.
The second stage, which might be termed “sentencing,”
encompasses the intracellular events that commit the cell
irreversibly to the death process. Finally, the cell enters
the “execution” stage, in which effector molecules, such as
particular nucleases and proteases, accomplish the overt
changes associated with apoptotic cell death. Each of these
hypothetical stages could itself involve a series of events.
To understand the apoptosis machinery, it will be neces-
sary to know both the identities of the molecular partici-
pants in the process and whether these molecules act in se-
quence or in parallel.
Figure 10. Summary of the approximate time intervals during
which various events occur in the cell-free system.The Journal of Cell Biology, Volume 137, 1997 1124
In this report we have investigated the function of sev-
eral components of the apoptotic machinery: SH2 do-
mains, the HM fraction, ceramide, ICE family proteases,
and Bcl-2, particularly with regard to the time intervals
during which these reagents could affect the kinetics of nu-
clear destruction in the cell-free system. The events we ex-
amined fell into three main time windows, as depicted in
Fig. 10. We propose that these experimentally defined
time periods correspond to the three conceptual phases of
apoptosis listed above.
The earliest distinguishable phase in the cell-free sys-
tem, which we call “initiation,” occurs in the first z60–90
min of incubation. (Events occurring before lysis of the
eggs may of course also be important for apoptosis initia-
tion, but are outside the scope of our investigations.) The
importance of SH2 domains and ceramide in this period
(Figs. 5 and 8) is consistent with the expectation that these
molecules would function in signal transduction. The sec-
ond period, which occurs z90–120 min after the start of in-
cubation, is the time when Bcl-2 protein, the heavy mem-
brane fraction, and the CPP32-related protease(s) act
(Figs. 6, 7, and 9). We propose that this represents a “sen-
tencing” phase, during which the system becomes commit-
ted irreversibly to the apoptotic pathway. Finally comes
the third, or “execution” phase, beginning after z1.5–2 h
of incubation. This is the period when overt changes occur
in the cell nuclei, culminating in extensive DNA fragmen-
tation and nuclear destruction. During this phase, we also
observed the cleavage of two polypeptides whose proteol-
ysis is characteristic of apoptotic cell death (25, 33): fodrin,
a cytoskeletal protein endogenous to the extract, and
lamin B, present in the rat liver nuclei added to the system
(18a). Our kinetics data suggest that the cleavage of fodrin
and lamin B occur later than the proteolytic events inhib-
ited by DEVD. Thus, this system appears to involve at
least two distinct protease activities, which may belong to
an enzymatic cascade.
It is important to note that the timing of apoptotic
events in the Xenopus system is somewhat variable from
extract to extract. This may be due, for example, to varia-
tion between animals in the proportion of eggs that are un-
dergoing apoptosis. In extreme cases, the onset of nuclear
destruction in a given extract can be as early as 45 min
or as late as 4 h after incubation has begun. However, in
the majority of experiments, the various events occurred
within 6 30 min of the times indicated in Fig. 10. This
means that, while the data in this report show that Bcl-2,
the HM fraction, and DEVD-inhibitable protease activity
all act in roughly the same time period, other approaches
have been required to determine the sequence in which
they act. Studies have now shown that mitochondria re-
lease cytochrome c into the cytosol, and that this event is
blocked by Bcl-2 (18, 48); cytochrome c, when present in
the cytosol, causes the activation of CPP32-related cas-
pases (23, 18a).
The occurrence of kinetically distinguishable phases in
apoptotic extracts now serves to underscore the value of
this cell-free system for dissecting the crucial intracellular
events involved in apoptosis. In particular, we expect this
system to be useful in uncovering both the activation
mechanisms and the critical substrates of the CPP32/Ced-3
family proteases.
Figure A1. Comparison of SH2 ligand peptides with regard to
their effects on the Xenopus cell-free apoptosis system. The experi-
ment was done as in Fig. 4, except that either the YEEI peptide,
or a synthetic peptide corresponding to the SH2 ligand domain of
phospholipase C (PLC)-g1 surrounding Y1021 (PLC peptide,
DNDY*IIPLPDPK; 35) was added to the system at the indicated
concentrations before incubation. Note that the PLC-g1 peptide
had no significant inhibitory activity in this system.
We are indebted to Rajasekaran Baskaran and Jean Wang for helpful ad-
vice and gifts of Abl, Src, and Stat1 SH2 domain GST fusions, as well as to
David Jones for a GST fusion of the SH2 domain of Grb-2. Gratitude is
expressed to our colleagues Ruth Kluck and Doug Green for advice and
comments on the manuscript.
This work is supported by grants to D.D. Newmeyer from the Ameri-
can Cancer Society (DB-97) and National Institutes of Health (NIH)
(GM50284) and to T. Mustelin from NIH (GM48960 and AI35603).
Received for publication 4 March 1996 and in revised form 25 March
1997.
References
1. Chittenden, T., E.A. Harrington, R. O’Connor, C. Flemington, R.J. Lutz,
G.I. Evan, and B.C. Guild. 1995. Induction of apoptosis by the Bcl-2 ho-
mologue Bak. Nature (Lond.). 374:733–736.
2. Cohen, G.B., R. Ren, and D. Baltimore. 1995. Modular binding domains in
signal transduction proteins. Cell. 80:237–248.
3. Cosulich, S.C., S. Green, and P.R. Clarke. 1996. Bcl-2 regulates activation
of apoptotic proteases in a cell-free system. Curr. Biol. 6:997–1005.
4. Couture, C., Z. Songyang, T. Jascur, S. Williams, P. Tailor, L.C. Cantley,
and T. Mustelin. 1996. Regulation of the Lck SH2 domain by tyrosine
phosphorylation. J. Biol. Chem. 271:24880–24884.
5. Darmon, A.J., D.W. Nicholson, and R.C. Bleackley. 1995. Activation of the
apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Na-
ture (Lond.). 377:446–448.
6. Duan, H., A.M. Chinnaiyan, P.L. Hudson, J.P. Wing. W.-W. He, and V.M.
Dixit. 1996. ICE-LAP3, a novel mammalian homologue of the Caenorhab-
ditis elegans cell death protein Ced-3, is activated during Fas- and tumor
necrosis factor-induced apoptosis. J. Biol. Chem. 271:1621–1625.
7. Ellis, R.E., J. Yuan, and H.R. Horvitz. 1991. Mechanisms and functions of
cell death. Annu. Rev. Cell Biol. 7:663–698.
8. Evans, E.K., W. Lu, S.L. Strum, B.J. Mayer, and S. Kornbluth. 1997. Crk is
required for apoptosis in Xenopus egg extracts. EMBO (Eur. Mol. Biol.
Organ.) J. 16:230–241.
9. Farrow, S.N., J.H.M. White, I. Martinou, T. Raven, K.-T. Pun, C.J. Grin-
ham, J.-C. Martinou, and R. Brown. 1995. Cloning of a bcl-2 homologue
by interaction with adenovirus E1B 19K. Nature (Lond.). 374:731–733.
10. Fath, I., F. Schweighoffer, I. Rey, M.C. Multon, J. Boiziau, M. Duchesne,
and B. Tocque. 1994. Cloning of a Grb2 isoform with apoptotic proper-
ties. Science (Lond.). 264:971–974.
11. Fernandes-Alnemri, T., G. Litwack, and E.S. Alnemri. 1994. CPP32, a
novel human apoptotic protein with homology to Caenorhabditis elegans
cell death protein Ced-3 and mammalian interleukin-1 beta-converting
enzyme. J. Biol. Chem. 269:30761–30764.
12. Fernandes-Alnemri, T., G. Litwack, and E.S. Alnemri. 1995. Mch2, a new
member of the apoptotic Ced-3/ICE cysteine protease gene family. Can-
cer Res. 55:2737–2742.
13. Fernandes-Alnemri, T., A. Takahashi, R. Armstrong, J. Krebs, L. Fritz,
K.J. Tomaselli, L. Wang, Z. Yu, C.M. Croce, and G. Salvesen. 1995.
Mch3, a novel human apoptotic cysteine protease highly related to
AppendixFarschon et al. Src Homology 2 Domains in Apoptosis 1125
CPP32. Cancer Res. 55:6045–6052.
14. Frorath, B., C.C. Abney, H. Berthold, M. Scanarini, and W. Northemann.
1992. Production of recombinant rat interleukin-6 in Escherichia coli us-
ing a novel highly efficient expression vector pGEX-3T. Biotechniques.
12:558–559.
15. Hengartner, M.O., and H.R. Horvitz. 1994. C. elegans cell survival gene
ced-9 encodes a functional homolog of the mammalian proto-oncogene
bcl-2. Cell. 76:665–676.
16. Kaufmann, S.H., S. Desnoyers, Y. Ottaviano, N.E. Davidson, and G.G.
Poirier. 1993. Specific proteolytic cleavage of poly (ADP-ribose) poly-
merase: an early marker of chemotherapy-induced apoptosis. Cancer
Res. 53:3976–3985.
17. Kiefer, M.C., M.J. Brauer, V.C. Powers, J.J. Wu, S.R. Umansky, L.D.
Tomei, and P.J. Barr. 1995. Modulation of apoptosis by the widely dis-
tributed Bcl-2 homologue Bak. Nature (Lond.). 374:736–739.
18. Kluck, R.M., E. Bossy-Wetzel, D.R. Green, and D.D. Newmeyer. 1997.
The release of cytochrome c from mitochondria: a primary site for Bcl-2
regulation of apoptosis. Science (Wash. DC). 275:1132–1136.
18a. Kluck, R.M., S.J. Martin, B.M. Hoffman, J.S. Zhou, D.R. Green, and
D.D. Newmeyer. 1997. Cytochrome c activation of CPP32-like proteoly-
sis plays a critical role in a Xenopus cell-free apoptosis system. EMBO
(Eur. Mol. Biol. Organ.) J. In press.
19. Lazebnik, Y.A., S. Cole, C.A. Cooke, W.G. Nelson, and WC. Earnshaw.
1993. Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a
model system for analysis of the active phase of apoptosis. J. Cell Biol.
123:7–22.
20. Lazebnik, Y.A., S.H. Kaufmann, S. Desnoyers, G.G. Poirier, and W.C.
Earnshaw. 1994. Cleavage of poly(ADP-ribose) polymerase by a protein-
ase with properties like ICE. Nature (Lond.). 371:346–347.
21. Lippke, J.A., Y. Gu, C. Sarnecki, P.R. Caron, and M.S.-S. Su. 1996. Identi-
fication and characterization of CPP34/Mch2 homolog 1, a novel cysteine
protease similar to CPP32. J. Biol. Chem. 271:1825–1828.
22. Liu, P., and R.G.W. Anderson. 1995. Compartmentalized production of
ceramide at the cell surface. J. Biol. Chem. 270:27179–27185.
23. Liu, X., C.N. Kim, J. Yang, R. Jemmerson, and X. Wang. 1996. Induction of
apoptotic program in cell-free extracts: requirement for dATP and cyto-
chrome c. Cell. 86:147–157.
24. Martin, S.J., D.D. Newmeyer, S. Mathias, D.M. Farschon, H.-G. Wang, J.C.
Reed, R.N. Kolesnick, and D.R. Green. 1995. Cell-free reconstitution of
Fas-, UV radiation- and ceramide-induced apoptosis. EMBO (Eur. Mol.
Biol. Organ.) J. 14:5191–5200.
25. Martin, S.J., G.A. O’Brien, W.K. Nishioka, A. McGahon, A. Mahboubi,
T.C. Saido, and D.R. Green. 1995. Proteolysis of fodrin (non-erythroid
spectrin) during apoptosis. J. Biol. Chem. 270:6425–6428.
26. Miura, M., H. Zhu, R. Rotello, E.A. Hartwieg, and J. Yuan. 1993. Induc-
tion of apoptosis is fibroblasts by IL-1b-converting enzyme, a mamma-
lian homolog of the C. elegans cell death gene ced-3. Cell. 75:653–660.
27. Mustelin, T., K.M. Coggeshall, and A. Altman. 1989. Rapid activation of
the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine
phosphatase. Proc. Natl. Acad. Sci. USA. 86:6302–6306.
28. Newmeyer, D.D., and K.L. Wilson. 1991. Egg extracts for nuclear import
and nuclear assembly reactions. Methods Cell Biol. 36:607–634.
29. Newmeyer, D.D., D.M. Farschon, and J.C. Reed. 1994. Cell-free apoptosis
in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an or-
ganelle fraction enriched in mitochondria. Cell. 79:353–364.
30. Nicholson, D.W., A. Ali, N.A. Thornberry, J.P. Vaillancourt, C.K. Ding,
M. Gallant, Y. Gareau, P.R. Griffin, M. Labelle, Y.A. Lazebnik et al.
1995. Identification and inhibition of the ICE/CED-3 protease necessary
for mammalian apoptosis. Nature (Lond.). 376:37–43.
31. Nosseri, C., S. Coppola, and L. Ghibelli. 1994. Possible involvement of
poly(ADP-ribosyl) polymerase in triggering stress-induced apoptosis.
Exp. Cell Res. 212:367–373.
32. Nuñez, G., and M.F. Clarke. 1994. The Bcl-2 family of proteins: regulators
of cell death and survival. Trends Cell Biol. 4:399–403.
33. Oberhammer, F.A., K. Hochegger, G. Fröschl, R. Tiefenbacher, and M.
Pavelka. 1994. Chromatin condensation during apoptosis is accompanied
by degradation of lamin A1B, without enhanced activation of cdc2 ki-
nase. J. Cell Biol. 126:827–837.
34. Osborne, B.A., and L.M. Schwartz. 1994. Essential genes that regulate ap-
optosis. Trends Cell Biol. 4:394–399.
35. Pascal, S.M., A.U. Singer, G. Gish, T. Yamazaki, S.E. Shoelson, T. Pawson,
L.E. Kay, and J.D. Forman-Kay. 1994. Nuclear magnetic resonance struc-
ture of an SH2 domain of phosholipase C-g1 complexed with a high affin-
ity binding peptide. Cell. 77:461–472.
36. Pawson, T. 1995. Protein modules and signalling networks. Nature (Lond.).
373:573–580.
37. Reed, J.C. 1994. Bcl-2 and the regulation of programmed cell death. J. Cell
Biol. 124:1–6.
38. Sato, T., M. Hanada, S. Bodrug, S. Irie, N. Iwama, L.H. Boise, C.B.
Thompson, E. Golemis, L. Fong, H.-G. Wang et al. 1994. Interactions
among members of the Bcl-2 protein family analyzed with a yeast two-
hybrid system. Proc. Natl. Acad. Sci. USA. 91:9238–9242.
39. Schlegel, J., I. Peters, S. Orrenius, D.K. Miller, N.A. Thornberry, T.-T.
Yamin, and D.W. Nicholson. 1996. CPP32/apopain is a key interleukin
1b converting enzyme-like protease involved in Fas-mediated apoptosis.
J. Biol. Chem. 271:1841–1844.
40. Shimizu, T., M. Kubota, A. Tanizawa, H. Sano, Y. Kasai, H. Hashimoto, Y.
Akiyama, and H. Mikawa. 1991. Inhibition of both etoposide-induced
DNA fragmentation and activation of poly(ADP-ribose) synthesis by
zinc ion. Biochem. Biophys. Res. Commun. 169:1172–1177.
41. Songyang, Z., S.E. Shoelson, M. Chaudhuri, G. Gish, T. Pawson, W.G.
Haser, F. King, T. Roberts, S. Ratnofsky, R.J. Lechleider et al. 1993. SH2
domains recognize specific phosphopeptide sequences. Cell. 72:767–778.
42. Steller, H. 1995. Mechanisms and genes of cellular suicide. Science (Wash.
DC). 267:1445–1449.
43. Tewari, M., L.T. Quan, K. O’Rourke, S. Desnoyers, Z. Zeng, D.R. Beidler,
G.G. Poirier, G.S. Salvesen, and V.M. Dixit. 1995. Yama/CPP32b, a
mammalian homolog of CED-3, is a CrmA-inhibitable protease that
cleaves the death substrate poly(ADP-ribose) polymerase Cell. 81:801–809.
44. Vaux, D.L., I.L. Weissman, and S. Kim. 1992. Prevention of programmed
cell death in Caenorhabditis elegans by human bcl-2. Science (Wash. DC).
258:1955–1957.
45. Vaux, D.L., G. Haecker, and A. Strasser. 1994. An evolutionary perspec-
tive on apoptosis. Cell. 76:777–779.
46. Wyllie, A.H., J.F.R. Kerr, and A.R. Currie. 1980. Cell death: the signifi-
cance of apoptosis. Int. Rev. Cytol. 68:251–306.
47. Yang, E., J. Zha, J. Jockel, L.H. Boise, C.B. Thompson, and S.J. Kors-
meyer. 1995. Bad, a heterodimeric partner for Bcl-xl and Bcl-2, displaces
Bax and promotes cell death. Cell. 80:285–291.
48. Yang, J., X. Liu, K. Bhalla, C.N. Kim, A.M. Ibrado, J. Cai, T.-I. Peng, D.P.
Jones, and X. Wang. 1997. Prevention of apoptosis by Bcl-2: release of
cytochrome c from mitochondria blocked. Science (Wash. DC). 275:
1129–1132.
49. Yin, X.-M., Z.N. Oltvai, and S.J. Korsmeyer. 1994. BH1 and BH2 domains
of Bcl-2 are required for inhibitio nof apoptosis and heterodimerization
with Bax. Nature (Lond.). 369:321–323.
50. Yuan, J., S. Shaham, S. Ledoux, H.M. Ellis, and H.R. Horvitz. 1993. The C.
elegans cell death gene ced-3 encodes a protein similar to mammalian in-
terleukin-1-b-converting enzyme. Cell. 75:641–652.